You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
SBC: EMMUNE INC Topic: RWe are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the preponderance of conserved but non-neutralizing epitopes in the full-length S protein. However, RBD-o ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Point-of-care lateral flow immunoassay for diagnosis of pertussis
SBC: DXDISCOVERY INC Topic: NIAIDPertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF
SBC: LEFLORE TECHNOLOGIES LLC Topic: 400Abstract.Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT The serious unmet need to address the excessive mortality observed in patients with Acute Respiratory Distress Syndrome (ARDS) has been brought sharply into focus by the current COVID-19 pandemic. In this R-44 application, Aqualung Therapeutics will address this therapeutic gap by utilizing a novel, humanized monoclonal antibody, ALT-100 mAb, which binds/neutralizes a novel ARDS target, e ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: 100Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Deep-CDS: Deep Learning Semantic Data Lake for Clinical Decision Support
SBC: INFOTECH SOFT, INC. Topic: 300More than 5 million patients are admitted annually to United States ICUs with average mortality rate reported ranging from 8-19%, or about 500,000 deaths annually. Sepsis is the leading cause of in-hospital mortality, where one in three inpatient deaths are due to sepsis. Incidence of sepsis has been increasing with 1.7 million sepsis cases and 270,000 deaths per year. Early identification of dete ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
SBC: Stemsynergy Therapeutic Topic: 102PROJECT SUMMARY/ABSTRACT The MYC family proteins are comprised of three paralogs termed c-myc, N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. While N-myc and L-myc drive oncogenesis in a small number of cancer types, the require ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
SBC: AQUALUNG THERAPEUTICS, CORP Topic: 300ABSTRACT Inflammatory bowel disease (IBD) is a debilitating disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A0 R42 STTR application focuses on a highly novel humanized monoclonal antibody (mAb), ALT-100, to target and neutralize eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern protein ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health